Nature Medicine, Published online: 11 June 2025; doi:10.1038/s41591-025-03722-7
In the 12-week, phase 2a DUET study, treatment with TERN-501, a thyroid hormone receptor β agonist, as monotherapy or in combination with TERN-101, a farnesoid X receptor agonist, resulted in dose-dependent reductions in liver fat content as compared to placebo in patients with presumed metabolic dysfunction-associated steatohepatitis.
Comments
No Trackbacks.